Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armida D'Incecco

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|February 18, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinibElisa Giovannetti, Paolo A Zucali, Godefridus J Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancersPierluigi Gasparini, Luciano Cascione, Lorenza Landi, et al.
Oncotarget|May 1, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 11, 2014
EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definitionVirginia Rotella, Lorenzo Fornaro, Enrico Vasile, et al.
Translational Lung Cancer Research|February 17, 2025
<i>MS4A15</i> gene expression as a prognostic marker for clinical outcomes in lung adenocarcinomaLingxiao Qiu, Tingcheng Li, Bin Qing, et al.
Pharmacogenomics|February 22, 2011
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patientsClara Lemos, Elisa Giovannetti, Paolo A Zucali, et al.
Oncotarget|February 8, 2019
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Claudia Ligorio, et al.
Oncotarget|January 23, 2016
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNAMarzia Del Re, Marcello Tiseo, Paola Bordi, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Glycobiology|February 14, 2007
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweedsAlbana Cumashi, Natalia A Ushakova, Marina E Preobrazhenskaya, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|February 18, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinibElisa Giovannetti, Paolo A Zucali, Godefridus J Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancersPierluigi Gasparini, Luciano Cascione, Lorenza Landi, et al.
Oncotarget|May 1, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 11, 2014
EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definitionVirginia Rotella, Lorenzo Fornaro, Enrico Vasile, et al.
Translational Lung Cancer Research|February 17, 2025
<i>MS4A15</i> gene expression as a prognostic marker for clinical outcomes in lung adenocarcinomaLingxiao Qiu, Tingcheng Li, Bin Qing, et al.
Pharmacogenomics|February 22, 2011
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patientsClara Lemos, Elisa Giovannetti, Paolo A Zucali, et al.
Oncotarget|February 8, 2019
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Claudia Ligorio, et al.
Oncotarget|January 23, 2016
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNAMarzia Del Re, Marcello Tiseo, Paola Bordi, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Glycobiology|February 14, 2007
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweedsAlbana Cumashi, Natalia A Ushakova, Marina E Preobrazhenskaya, et al.
Pageof 4